TrialJournal for immunotherapy of cancer2023

Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016).

Benedetta Pellegrino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.